2.1 Iron Metabolism & Iron Deficiency Anemia

Iron Metabolism & Iron Deficiency Anemia

Microcytic hypochromic anemias represent a fundamental category of erythroid pathology defined by a mean corpuscular volume (MCV) < 80 fL and a mean corpuscular hemoglobin concentration (MCHC) < 32 g/dL. Because hemoglobin synthesis requires three core components—adequate bioavailable iron, intact protoporphyrin/heme ring synthesis, and balanced globin chain production—a quantitative defect in any of these pathways restricts cytoplasmic hemoglobinization. This restriction forces developing erythroblasts to undergo extra mitotic divisions, yielding microcytic, poorly hemoglobinized red blood cells.

                    ┌─────────────────────────────────────────┐
                    │   Microcytic Hypochromic Anemias         │
                    │       (MCV < 80 fL, MCHC < 32 g/dL)      │
                    └────────────────────┬────────────────────┘
                                         │
         ┌───────────────────────────────┼───────────────────────────────┐
         │                               │                               │
┌────────┴─────────┐            ┌────────┴─────────┐            ┌────────┴─────────┐
│  Iron Deficient  │            │ Heme/Porphyrin   │            │  Globin Chain    │
│   Availability   │            │ Synthesis Defect │            │ Synthesis Defect │
├──────────────────┤            ├──────────────────┤            ├──────────────────┤
│ • Iron Deficiency│            │ • Sideroblastic  │            │ • Alpha Thal     │
│   Anemia (IDA)   │            │   Anemia (SA)    │            │ • Beta Thal      │
│ • Anemia Chronic │            │ • Lead Poisoning │            │   Minor/Trait    │
│   Disease (ACD)  │            │                  │            │                  │
└──────────────────┘            └──────────────────┘            └──────────────────┘

---

Systemic Iron Metabolism & Kinetics

The human body contains 3.5 to 5.0 grams of total iron, tightly partitioned between functional compartments (hemoglobin ~65–70%, myoglobin ~4%, respiratory heme enzymes ~1%) and storage compartments (ferritin and hemosiderin ~25–30%). Plasma transferrin accounts for less than 0.1% of total body iron (~3 mg) but represents the vital dynamic transit pool.

Dietary Absorption and Enterocyte Transport

Daily dietary intake averages 10–20 mg of iron, but only 1.0 to 2.0 mg is absorbed in the duodenum and upper jejunum to balance obligatory daily losses from desquamated skin, gut enterocytes, and minor mucosal bleeding:

1. Heme Iron ($Fe^{2+}$): Sourced from animal meat hemoglobin/myoglobin; absorbed intact via heme carrier protein 1 (HCP1) with high bioavailability (20–30%). Once internalized, heme oxygenase-1 releases ferrous iron ($Fe^{2+}$).
2. Non-Heme Iron ($Fe^{3+}$): Sourced from plant and fortified foods; exists primarily as insoluble ferric ($Fe^{3+}$) complexes. Gastric hydrochloric acid solubilizes $Fe^{3+}$, and the apical brush-border ferric reductase duodenal cytochrome b (DCYTB) reduces $Fe^{3+}$ to ferrous iron ($Fe^{2+}$).
3. Apical Influx: Ferrous iron is transported across the apical enterocyte membrane via Divalent Metal Transporter 1 (DMT1) (solute carrier family 11 member 2, SLC11A2), co-transported with $H^+$.
4. Basolateral Efflux: Intracellular iron is transported across the basolateral membrane into the portal circulation by ferroportin (solute carrier family 40 member 1, SLC40A1), the only known mammalian cellular iron exporter.
5. Oxidation & Loading: As iron exits ferroportin, the transmembrane copper-dependent ferroxidase hephaestin (and circulating ceruloplasmin) oxidizes $Fe^{2+}$ back to $Fe^{3+}$, enabling safe incorporation into circulating apotransferrin to form diferric transferrin.

Hepcidin: The Master Systemic Regulator

Hepcidin is a 25-amino acid peptide hormone synthesized and secreted by hepatocytes that exerts negative feedback control over systemic iron flow. When hepatic iron stores rise or systemic inflammation occurs (driven by pro-inflammatory cytokines, especially interleukin-6 [IL-6] via the STAT3 signaling pathway), hepatic hepcidin transcription is strongly upregulated.

• Mechanism of Action: Circulating hepcidin binds directly to the extracellular loop of ferroportin on duodenal enterocytes, splenic/hepatic reticuloendothelial macrophages, and hepatocytes. This binding induces ferroportin phosphorylation, internalization, ubiquitin-mediated endocytosis, and lysosomal degradation.
• Physiological Result: With ferroportin destroyed, intestinal iron absorption is blocked, and iron recovered from senescent red blood cells remains trapped inside macrophage lysosomes, causing hypoferremia.

[Inflammation / IL-6] or [High Iron Stores]
                 │
                 ▼
   [↑ Hepatic Hepcidin Synthesis]
                 │
                 ▼
 [Binds Basolateral Ferroportin]
                 │
                 ▼
[Ferroportin Internalized & Degraded]
                 │
         ┌───────┴───────────────────────┐
         ▼                               ▼
[Duodenal Iron Absorption       [Macrophage Iron Recycling
       BLOCKED]                       TRAPPED]
         │                               │
         └───────────────┬───────────────┘
                         ▼
        [Hypoferremia / Iron Sequestration]

Transferrin Transport and Cellular Storage

• Transferrin: A 76-kDa plasma glycoprotein synthesized by the liver with two high-affinity binding sites for ferric iron ($Fe^{3+}$). Total Iron Binding Capacity (TIBC, normal: $250\text{ to }450\text{ }\mu\text{g/dL}$) directly quantifies circulating transferrin concentration. Serum Iron (normal: $60\text{ to }170\text{ }\mu\text{g/dL}$) reflects transferrin-bound iron. Transferrin Saturation ($[\text{Serum Iron} / \text{TIBC}] \times 100$, normal: $20%\text{ to }50%$) indicates the percentage of binding sites occupied.
• Cellular Uptake: Erythroid precursors express high levels of Transferrin Receptor 1 (TfR1 / CD71). Diferric transferrin binds TfR1, undergoes clathrin-coated endocytosis, and acidic endosomal pH releases $Fe^{3+}$. Endosomal ferric reductase (STEAP3) reduces iron to $Fe^{2+}$, which DMT1 transports into the cytosol for delivery to the mitochondria (via mitoferrin-1) for heme synthesis.
• Ferritin & Hemosiderin: Excess cytosolic iron is safely sequestered inside ferritin, a 24-subunit spherical protein shell (apoferritin) capable of holding up to 4,500 iron atoms as ferrihydrite crystals. Serum ferritin (normal: $15\text{ to }300\text{ ng/mL}$) correlates directly with total body macrophage and hepatocyte iron stores. When iron stores exceed ferritin storage capacity, lysosomal degradation forms hemosiderin, an insoluble, partially denatured ferritin aggregate that stains intensely with Prussian blue.

---

Iron Deficiency Anemia (IDA)

Iron Deficiency Anemia develops when systemic iron demand exceeds bioavailability over an extended period. Common etiologies include chronic blood loss (gastrointestinal hemorrhage, peptic ulcers, colon carcinoma, angiodysplasia, menorrhagia), increased physiological requirement (pregnancy, lactation, rapid infant/adolescent growth spurts), malabsorption (celiac disease, post-gastrectomy, bariatric Roux-en-Y surgery, Helicobacter pylori gastritis), or inadequate dietary intake.

The Three Sequential Stages of Iron Depletion

STAGE 1: Storage Iron Depletion (Prelatent)
  • Bone marrow macrophage iron: DECREASED/ABSENT
  • Serum Ferritin: DECREASED (<15-20 ng/mL)
  • Serum Iron, TIBC, % Saturation, Hemoglobin, MCV, RDW: NORMAL
                    │
                    ▼
STAGE 2: Iron-Deficient Erythropoiesis (Latent)
  • Serum Iron: DECREASED (<50 µg/dL)
  • TIBC: ELEVATED (>450 µg/dL)
  • Transferrin Saturation: DECREASED (<15-16%)
  • Soluble Transferrin Receptor (sTfR): ELEVATED
  • Free Erythrocyte Protoporphyrin (FEP / ZPP): ELEVATED
  • Hemoglobin & MCV: NORMAL or BORDERLINE LOW; RDW: ELEVATED
                    │
                    ▼
STAGE 3: Overt Iron Deficiency Anemia (Frank Anemia)
  • Hemoglobin & Hematocrit: MARKEDLY DECREASED
  • MCV (<70-80 fL) & MCHC (<30-32 g/dL): MARKEDLY DECREASED
  • Serum Ferritin: VERY LOW (<10-15 ng/mL)
  • Transferrin Saturation: CRITICALLY LOW (<10%)
  • Peripheral Smear: Microcytes, Hypochromia, Pencil/Cigar Cells

1. Stage 1: Storage Iron Depletion (Prelatent Stage)
   • Progressive exhaustion of macrophage storage iron in the bone marrow, liver, and spleen.
   • Serum ferritin drops below 15–20 ng/mL.
   • Serum iron, TIBC, transferrin saturation, hemoglobin, hematocrit, and red cell indices remain completely normal because iron supply to erythroblasts is maintained from depleting stores.
   • Bone marrow Prussian blue stain reveals an absence of storage hemosiderin in reticuloendothelial cells.
2. Stage 2: Iron-Deficient Erythropoiesis (Latent Stage)
   • Storage iron is completely exhausted; iron delivery to the bone marrow becomes rate-limiting for heme synthesis.
   • Serum iron falls ($<50\text{ }\mu\text{g/dL}$), hepatic transferrin output increases causing elevated TIBC ($>450\text{ }\mu\text{g/dL}$), and transferrin saturation drops below 15–16%.
   • Erythroblasts upregulate surface transferrin receptors, leading to shedding and elevated soluble transferrin receptor (sTfR) levels in serum.
   • Because iron is unavailable to insert into protoporphyrin IX, zinc is substituted by ferrochelatase, causing marked accumulation of Zinc Protoporphyrin (ZPP) / Free Erythrocyte Protoporphyrin (FEP).
   • Hemoglobin and MCV remain within lower reference limits, but the Red Cell Distribution Width (RDW) widens ($>15.0%$) as microcytic cells enter the circulation.
3. Stage 3: Overt Iron Deficiency Anemia (Frank Anemia)
   • Severe quantitative deficit in total hemoglobin mass.
   • Hemoglobin, hematocrit, MCV ($<70\text{ to }80\text{ fL}$), MCH ($<27\text{ pg}$), and MCHC ($<32\text{ g/dL}$) drop significantly.
   • Peripheral blood smear reveals prominent microcytosis, marked hypochromia (central pallor exceeding 1/3 to 1/2 of the erythrocyte diameter), severe anisocytosis, and poikilocytosis.
   • Pencil cells (cigar cells / elongated elliptocytes) and target cells (codocytes) are characteristic morphologic hallmarks.
   • Reactive thrombocytosis (platelet count often $450,000\text{ to }800,000/\mu\text{L}$) frequently occurs due to shared megakaryocyte-erythroid progenitor stimulation and structural homology between elevated erythropoietin and thrombopoietin.

---